Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance

The Journal of Allergy and Clinical Immunology
Annemiek Vermeeren, James F O'Hanlon

Abstract

Fexofenadine is the hydrochloride salt of terfenadine's active metabolite. Fexofenadine's effects on performance were assessed in this study for the purpose of determining its safety of use by patients who engage in potentially dangerous activities, especially car driving. Fexofenadine was administered in daily doses of 120 or 240 mg, each in single and divided units given over 5 days. Two milligrams of clemastine given twice daily and placebo were given in similar series. Twenty-four healthy volunteers (12 men, 12 women; age range, 21 to 45 years) participated in a double-blind six-way crossover study. Psychomotor tests (critical tracking, choice reaction time, and sustained attention) and a standardized actual driving test were undertaken between 1.5 to 4 hours after administration of the morning dose on days 1, 4, and 5 of each series. On day 5, subjects were challenged with a moderate alcohol dose before testing. Fexofenadine did not impair driving performance. On the contrary, driving performance was consistently better during twice daily treatment with 120 mg fexofenadine than during treatment with placebo, significantly so on day 4. Both of the 240 mg/day regimens significantly attenuated alcohol's adverse effect on driv...Continue Reading

Citations

Jun 13, 2006·Psychopharmacology·Eef L TheunissenJohannes G Ramaekers
May 10, 2005·Immunology and Allergy Clinics of North America·Bruce G Bender
Oct 8, 2003·The Journal of Allergy and Clinical Immunology·Suzanne G Meeves, Sireesh Appajosyula
Mar 31, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Joris C Verster, Edmund R Volkerts
May 31, 2003·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Lyndon MansfieldSuzanne G Meeves
Sep 4, 2003·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Paul Charles PotterChristoffel Hendrik Van Niekerk
May 11, 2002·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·I HindmarchS Kimber
Jun 10, 2000·The British Journal of Dermatology·S DharG Mistri
Nov 6, 2002·Journal of American College Health : J of ACH·Jonathan HowlandMichelle Kupka
Jul 28, 2004·Traffic Injury Prevention·J Michael WalshAlain G Verstraete
Sep 12, 2009·Journal of Clinical Psychopharmacology·Eef L TheunissenJohannes G Ramaekers
Oct 7, 2000·BMJ : British Medical Journal·J G Ramaekers, A Vermeeren
Jul 15, 2005·Skin Pharmacology and Physiology·Malcolm W Greaves
Jan 11, 2014·Psychopharmacology·Stefan JongenAnnemiek Vermeeren
Dec 5, 2000·British Journal of Anaesthesia·S A GrantG N Kenny
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J MasonN Rao
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·F E Simons
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·I Hindmarch, Z Shamsi
Nov 22, 2002·Current Medical Research and Opinion·Stanley R MohlerSuzanne G Meeves
Apr 26, 2006·The British Journal of Dermatology·R A Sabroe, M W Greaves
Mar 22, 2016·Disease-a-month : DM·David VearrierKristin McCloskey
Feb 10, 2007·Current Medical Research and Opinion·Martin Scharf, David Berkowitz
Jan 5, 2006·British Journal of Clinical Pharmacology·Eef L TheunissenJohannes G Ramaekers
Aug 9, 2003·Expert Opinion on Drug Safety·Garry M Walsh
May 31, 2002·Expert Opinion on Investigational Drugs·John J Oppenheimer, Thomas B Casale
Jan 28, 2014·International Journal of Occupational Medicine and Environmental Health·Axel MuttrayStephan Letzel
Dec 23, 2011·Allergology International : Official Journal of the Japanese Society of Allergology·Goro TakahashiKeisuke Masuyama
Jan 30, 2014·The Annals of Pharmacotherapy·Amanda Hetland, David B Carr
Dec 7, 2013·Journal of Psychopharmacology·Claire O'BrienMike Harris
Jun 9, 1999·The Journal of Allergy and Clinical Immunology·M H TerrienF Spertini
Sep 22, 2005·Journal of Psychopharmacology·Eef L TheunissenJohannes G Ramaekers
Jan 23, 2008·Journal of Psychopharmacology·P van RuitenbeekWj Riedel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.